Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sputum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7293   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    620 result(s) found for: Sputum. Displaying page 1 of 31.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-004377-44 Sponsor Protocol Number: Ambroxpall Start Date*: 2021-08-24
    Sponsor Name:Med. Univ. Wien, Innere Med. I, Abt. f. Palliativmedizin
    Full Title: Ambroxol inhalation for mucus clearance in palliative care patients - a randomized placebo-controlled double-blind pilot study.
    Medical condition: cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000244-26 Sponsor Protocol Number: PC-ASP-004 Start Date*: 2018-08-21
    Sponsor Name:Pulmocide Ltd
    Full Title: A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe ast...
    Medical condition: Pulmonary aspergillosis and candidiasis of lung
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    20.0 100000004862 10007155 Candidiasis of lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002014-52 Sponsor Protocol Number: FOOTSTEP Start Date*: 2019-01-23
    Sponsor Name:University Medical Center Utrecht
    Full Title: DUAL HOMING MECHANISMS OF EOSINOPHILS TO THE SPUTUM; ONLY ONE OF WHICH IS SENSITIVE FOR MEPOLIZUMAB
    Medical condition: severe eosinophilic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001412-30 Sponsor Protocol Number: HMR3647A/4020 Start Date*: 2005-12-02
    Sponsor Name:Laboratoire Aventis
    Full Title: An open-label, randomized, multicenter, clinical study to compare the effects of telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide resistance of Streptococcus pneumon...
    Medical condition: Patients with acute exacerbation of chronic bronchitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-004389-17 Sponsor Protocol Number: TR02-103 Start Date*: 2005-12-28
    Sponsor Name:Transave, Inc
    Full Title: SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA
    Medical condition: Cystic Fibrosis with mild to moderate obstructive lung disease and chronic infection with Pseudomonas aeruginosa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000753-35 Sponsor Protocol Number: D0520C00010 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Bronchiectasis
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006445 Bronchiectasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003374-14 Sponsor Protocol Number: SAV008-01 Start Date*: 2018-04-06
    Sponsor Name:Savara ApS
    Full Title: An Open-label, non-controlled, multicenter, Pilot clinical Trial of Inhaled Molgramostim in subjects with Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection
    Medical condition: Treatment-resistant pulmonary non-tuberculosis mycobacterial (NTM) infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10062207 Mycobacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000243-87 Sponsor Protocol Number: PC_ASP_003 Start Date*: 2018-11-19
    Sponsor Name:Pulmocide Ltd
    Full Title: An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection.
    Medical condition: Pulmonary aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004381-33 Sponsor Protocol Number: CQAW039A2127 Start Date*: 2019-12-11
    Sponsor Name:Novartis Pharma AG
    Full Title: Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipiprant (QAW039) in moderate-severe asthma patients with high sputum and...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023828-24 Sponsor Protocol Number: 09107 Start Date*: 2011-06-09
    Sponsor Name:University of Nottingham
    Full Title: The effect of Thalidomide on sputum biomarkers in IPF cough.
    Medical condition: Cough in Idiopathic Pulmonary fibrosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002584-90 Sponsor Protocol Number: D1511C00002 Start Date*: 2005-08-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Spu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002202-31 Sponsor Protocol Number: POL7080-002 Start Date*: 2013-09-11
    Sponsor Name:Polyphor Ltd.
    Full Title: A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of...
    Medical condition: Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000264-17 Sponsor Protocol Number: ARD-3100-0703 Start Date*: 2008-08-19
    Sponsor Name:Aradigm Corporation
    Full Title: A MULTI-CENTER, OPEN-LABEL, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECT ON SPUTUM PSEUDOMONAS AERUGINOSA DENSITY OF INHALED LIPOSOMAL CIPROFLOXACIN HYDROCHLORIDE IN ADUL...
    Medical condition: To evaluate the safety, tolerability, and effect on sputum P. aeruginosa density of two dose levels of liposomal ciprofloxacin hydrochloride for inhalation in adult subjects with non-CF bronchiecta...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002938-20 Sponsor Protocol Number: 13031 Start Date*: 2013-11-08
    Sponsor Name:University of Nottingham
    Full Title: An open label trial of azithromycin in chronic productive cough
    Medical condition: The medical condition that will be investigated is that of chronic productive cough (with or without a diagnosis of asthma but without a diagnosis of bronchiectasis, smoking related chronic bronchi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001626-22 Sponsor Protocol Number: RML-TB Start Date*: 2022-03-28
    Sponsor Name:Vall d'Hebron Institute of Research
    Full Title: A Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezoli...
    Medical condition: Smear-positive rifampicin-sensitive pulmonary Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006276-11 Sponsor Protocol Number: VR496/005 Start Date*: 2008-09-01
    Sponsor Name:Vectura Limited
    Full Title: A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cys...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002854-39 Sponsor Protocol Number: CAIN457A2104 Start Date*: 2009-01-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placeb...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005452-41 Sponsor Protocol Number: DPM-B-301 Start Date*: 2006-05-26
    Sponsor Name:Pharmaxis UK Limited
    Full Title: A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic tr...
    Medical condition: Bronchiectasis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004966-13 Sponsor Protocol Number: CQAW039A2208 Start Date*: 2011-12-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 on sputum eosinophil levels and other efficacy outcomes in patients with sputum eosinophilia and pers...
    Medical condition: sputum eosinophilia and moderate-to-severe asthma (GINA 2-5) incompletely controlled on current therapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10062305 Sputum eosinophils increased LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000398-19 Sponsor Protocol Number: AGO/2016/002 Start Date*: 2016-03-08
    Sponsor Name:Ghent University
    Full Title: Pilot study: pharmacokinetics of beta-lactam antibiotics, piperacillin-tazobactam, ceftazidim and meropenem in blood and sputum of cystic fibrosis patients.
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 07 21:10:52 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA